Semaglutide 5mg GLP-1 receptor agonist research peptide

Semaglutide GLP-1 receptor agonist peptide: a research overview

Few peptides have been studied as thoroughly as semaglutide. Here's a cozy summary of the major published trials and where things stand.

Please note: Snowman Research does not offer dosing information or usage guidance of any kind. Everything we list, this item included, is sold strictly for research purposes and nothing else.

Published findings

Semaglutide's evidence base rests on large randomized phase 3 trials. In the STEP 1 trial (NEJM, 2021), adults with overweight or obesity who also followed a lifestyle program saw an average body-weight change of −14.9% by week 68, versus −2.4% on placebo ^[1]. The SELECT trial (NEJM, 2023) followed 17,604 adults who had cardiovascular disease and overweight or obesity without diabetes for a mean of 39.8 months; major cardiovascular events occurred in 6.5% of the semaglutide group and 8.0% of the placebo group (hazard ratio 0.80), while stopping treatment because of adverse events was more common on semaglutide (16.6% vs 8.2%) ^[2].

Mechanism at a glance

At the receptor level, semaglutide stands in for glucagon-like peptide-1, switching on that hormone's receptor ^[3]. Its labeled uses include glycemic control in type 2 diabetes ^[4].

Regulatory & WADA notes

Semaglutide is the active ingredient in two FDA-approved medicines. Ozempic is indicated for glycemic control in adults with type 2 diabetes and for reducing certain cardiovascular and kidney risks in that population ^[4]. Wegovy is indicated for long-term weight reduction, for cardiovascular risk reduction in adults with established cardiovascular disease and obesity or overweight, and for noncirrhotic MASH with moderate-to-advanced fibrosis ^[3]. This research material is not one of those products. In sport, semaglutide does not appear on WADA's 2026 Prohibited List; WADA's 2026 Monitoring Program tracks markers of semaglutide and tirzepatide ^[5].

Thanks for reading. Stay warm, and keep your bench notes tidy.

Further reading

1. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. PMID 33567185. https://pubmed.ncbi.nlm.nih.gov/33567185/
2. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. PMID 37952131. https://pubmed.ncbi.nlm.nih.gov/37952131/
3. DailyMed - WEGOVY- semaglutide injection, solution. WEGOVY prescribing information, DailyMed (U.S. National Library of Medicine). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
4. DailyMed - OZEMPIC- semaglutide injection, solution. OZEMPIC prescribing information, DailyMed (U.S. National Library of Medicine). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79
5. The 2026 Monitoring Program. World Anti-Doping Agency, 2026 Monitoring Program. https://www.wada-ama.org/sites/default/files/2025-09/2026_list_monitoring_program_en_final_clean_september_2025.pdf

For laboratory research use only. This product is not intended for human or veterinary use and is not an FDA-approved drug; nothing on this page is medical advice. You must be 21 or older to purchase.